<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               <BR>                  1<BR>                  4<BR>                    <BR>                  CLINICAL STUDIES<BR>               <BR>               <BR>               <BR>                  <BR>                     Figure 1  Disease-Free Survival (Median follow-up 73 months, ITT Approach)<BR>                     <BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     Figure 2  Kaplan-Meier Estimates of Time to Progression (Tamoxifen Study)<BR>                     <BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     Figure 3  Survival by Randomized Treatment Arm<BR>                     <BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     Figure 4  Kaplan-Meier Estimates of Time to Progression (Megestrol Acetate Study)<BR>                     <BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     Figure 5  Kaplan-Meier Estimates of Time to Progression (Aminoglutethimide Study)<BR>                     <BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     <BR>                        14.1 <BR>                        Updated <BR>                        Adjuvant Treatment of Early Breast Cancer<BR>                         <BR>                     <BR>                     <BR>                        In a multicenter study enrolling over 8,000 postmenopausal women with resected, receptor-positive early breast cancer, one of the following treatments was randomized in a double-blind manner: <BR>                        <BR>		     <BR>	Option 1:<BR>                        <BR>                           tamoxifen for 5 years<BR><BR>                           <BR>                           Femara for 5 years<BR><BR>                           <BR>                           tamoxifen for 2 years followed by Femara for 3 years<BR><BR>                           <BR>                           Femara for 2 years followed by tamoxifen for 3 years<BR>                        <BR>                        Option 2:<BR>                        <BR>                           tamoxifen for 5 years<BR><BR>                           <BR>                           Femara for 5 years<BR>                        <BR>                        The study in the adjuvant setting, BIG 1-98 was designed to answer two primary questions: whether Femara for 5 years was superior to tamoxifen for 5 years (Primary Core Analysis) and whether switching endocrine treatments at 2 years was superior to continuing the same agent for a total of 5 years (Sequential Treatments Analysis). Selected baseline characteristics for the study population are shown in Table 5.<BR>                        The primary endpoint of this trial was disease-free survival (DFS) (i.e., interval between randomization and earliest occurrence of a local, regional, or distant recurrence, or invasive contralateral breast cancer, or death from any cause). The secondary endpoints were overall survival (OS), systemic disease-free survival (SDFS), invasive contralateral breast cancer, time to breast cancer recurrence (TBR) and time to distant metastasis (TDM).<BR>                        The Primary Core Analysis (PCA) included all patients and all follow-up in the monotherapy arms in both randomization options, but follow-up in the two sequential treatments arms was truncated 30 days after switching treatments. The PCA was conducted at a median treatment duration of 24 months and a median follow-up of 26 months. Femara was superior to tamoxifen in all endpoints except overall survival and contralateral breast cancer [e.g., DFS: hazard ratio, HR 0.79; 95% CI (0.68, 0.92); P=0.002; SDFS: HR 0.83; 95% CI (0.70, 0.97); TDM: HR 0.73; 95% CI (0.60, 0.88); OS: HR 0.86; 95% CI (0.70, 1.06). <BR>                        In 2005, based on recommendations by the independent Data Monitoring Committee, the tamoxifen arms were unblinded and patients were allowed to complete initial adjuvant therapy with Femara (if they had received tamoxifen for at least 2 years) or to start extended adjuvant treatment with Femara (if they had received tamoxifen for at least 4.5 years) if they remained alive and disease-free. In total, 632 patients crossed to Femara or another aromatase inhibitor. Approximately 70% (448) of these 632 patients crossed to Femara to complete initial adjuvant therapy and most of these crossed in years 3 to 4. All of these patients were in Option 1. A total of 184 patients started extended adjuvant therapy with Femara (172 patients) or with another aromatase inhibitor (12 patients). To explore the impact of this selective crossover, results from analyses censoring follow-up at the date of the selective crossover (in the tamoxifen arm) are presented for the Monotherapy Arms Analysis (MAA).<BR>                        The PCA allowed the results of Femara for 5 years compared with tamoxifen for 5 years to be reported in 2005 after a median follow-up of only 26 months. The design of the PCA is not optimal to evaluate the effect of Femara after a longer time (because follow-up was truncated in two arms at around 25 months). The Monotherapy Arms Analysis (ignoring the two sequential treatment arms) provided follow-up equally as long in each treatment and did not over-emphasize early recurrences as the PCA did. The MAA thus provides the clinically appropriate updated efficacy results in answer to the first primary question, despite the confounding of the tamoxifen reference arm by the selective crossover to Femara. The updated results for the MAA are summarized in Table 6. Median follow-up for this analysis is 73 months.<BR>                        The Sequential Treatments Analysis (STA) addresses the second primary question of the study. The primary analysis for the Sequential Treatments Analysis (STA) was from switch (or equivalent time-point in monotherapy arms) + 30 days (STA-S) with a two-sided test applied to each pair-wise comparison at the 2.5% level. Additional analyses were conducted from randomization (STA-R) but these comparisons (added in light of changing medical practice) were under-powered for efficacy.<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><BR>                           <caption>Table 5:  Adjuvant Study - Patient and Disease Characteristics (ITT Population)</caption><BR>                           <col width="207"/><BR>                           <col width="103"/><BR>                           <col width="103"/><BR>                           <col width="103"/><BR>                           <col width="103"/><BR>                           <tbody><BR>                              <tr><BR>                                 <td styleCode="Toprule "/><BR>                                 <td styleCode="Toprule " colspan="2" align="center"><BR>                                    <content styleCode="bold">Primary Core Analysis (PCA)</content><BR>                                 </td><BR>                                 <td styleCode="Toprule " colspan="2" align="center"><BR>                                    <content styleCode="bold">Monotherapy Arms Analysis (MAA)</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td/><BR>                                 <td align="center"><BR>                                    <content styleCode="bold">Femara</content><BR>                                 </td><BR>                                 <td align="center"><BR>                                    <content styleCode="bold">t</content><BR>                                    <content styleCode="bold">amoxifen</content><BR>                                 </td><BR>                                 <td align="center"><BR>                                    <content styleCode="bold">Femara</content><BR>                                 </td><BR>                                 <td align="center"><BR>                                    <content styleCode="bold">t</content><BR>                                    <content styleCode="bold">amoxifen</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td/><BR>                                 <td align="center"><BR>                                    <content styleCode="bold">N=4003</content><BR>                                 </td><BR>                                 <td align="center"><BR>                                    <content styleCode="bold">N=4007</content><BR>                                 </td><BR>                                 <td align="center"><BR>                                    <content styleCode="bold">N=2463</content><BR>                                 </td><BR>                                 <td align="center"><BR>                                    <content styleCode="bold">N=2459</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <content styleCode="bold">Characteristic</content><BR>                                 </td><BR>                                 <td align="center"><BR>                                    <content styleCode="bold">n (%)</content><BR>                                 </td><BR>                                 <td align="center"><BR>                                    <content styleCode="bold">n (%)</content><BR>                                 </td><BR>                                 <td align="center"><BR>                                    <content styleCode="bold">n (%)</content><BR>                                 </td><BR>                                 <td align="center"><BR>                                    <content styleCode="bold">n (%)</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Toprule ">Age (median, years)</td><BR>                                 <td styleCode="Toprule " align="center">61</td><BR>                                 <td styleCode="Toprule " align="center">61</td><BR>                                 <td styleCode="Toprule " align="center">61</td><BR>                                 <td styleCode="Toprule " align="center">61</td><BR>                              </tr><BR>                              <tr><BR>                                 <td>Age range (years)</td><BR>                                 <td align="center">38-89</td><BR>                                 <td align="center">39-90</td><BR>                                 <td align="center">38-88</td><BR>                                 <td align="center">39-90</td><BR>                              </tr><BR>                              <tr><BR>                                 <td>Hormone receptor status (%)</td><BR>                                 <td align="center"/><BR>                                 <td align="center"/><BR>                                 <td align="center"/><BR>                                 <td align="center"/><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	ER+ and/or PgR+</td><BR>                                 <td align="center">99.7</td><BR>                                 <td align="center">99.7</td><BR>                                 <td align="center">99.7</td><BR>                                 <td align="center">99.7</td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	Both unknown</td><BR>                                 <td align="center">0.3</td><BR>                                 <td align="center">0.3</td><BR>                                 <td align="center">0.3</td><BR>                                 <td align="center">0.3</td><BR>                              </tr><BR>                              <tr><BR>                                 <td>Nodal status (%)</td><BR>                                 <td align="center"/><BR>                                 <td align="center"/><BR>                                 <td align="center"/><BR>                                 <td align="center"/><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	Node negative</td><BR>                                 <td align="center">52</td><BR>                                 <td align="center">52</td><BR>                                 <td align="center">50</td><BR>                                 <td align="center">52</td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	Node positive</td><BR>                                 <td align="center">41</td><BR>                                 <td align="center">41</td><BR>                                 <td align="center">43</td><BR>                                 <td align="center">41</td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	Nodal status unknown</td><BR>                                 <td align="center">7</td><BR>                                 <td align="center">7</td><BR>                                 <td align="center">7</td><BR>                                 <td align="center">7</td><BR>                              </tr><BR>                              <tr><BR>                                 <td>Prior adjuvant chemotherapy (%)</td><BR>                                 <td align="center">24</td><BR>                                 <td align="center">24</td><BR>                                 <td align="center">24</td><BR>                                 <td align="center">24</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR><BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><BR>                           <caption>Table 6:  Updated Adjuvant Study Results - Monotherapy Arms Analysis (Median Follow-up 73 Months)</caption><BR>                           <col width="186"/><BR>                           <col width="56"/><BR>                           <col width="70"/><BR>                           <col width="60"/><BR>                           <col width="72"/><BR>                           <col width="60"/><BR>                           <col width="138"/><BR>                           <col width="48"/><BR>                           <tbody><BR>                              <tr><BR>                                 <td styleCode="Toprule " align="center"/><BR>                                 <td styleCode="Toprule " align="center"/><BR>                                 <td styleCode="Toprule " colspan="2" align="center"><BR>                                    <content styleCode="bold">Femara</content><BR>                                    <br/><BR>                                    <content styleCode="bold">N=2463</content><BR>                                 </td><BR>                                 <td styleCode="Toprule " colspan="2" align="center"><BR>                                    <content styleCode="bold">t</content><BR>                                    <content styleCode="bold">amoxifen</content><BR>                                    <br/><BR>                                    <content styleCode="bold">N=2459</content><BR>                                 </td><BR>                                 <td styleCode="Toprule " align="center"><BR>                                    <content styleCode="bold">Hazard ratio</content><BR>                                 </td><BR>                                 <td styleCode="Toprule " align="center"/><BR>                              </tr><BR>                              <tr><BR>                                 <td/><BR>                                 <td/><BR>                                 <td align="center"><BR>                                    <content styleCode="bold">Events</content><BR>                                    <br/><BR>                                    <content styleCode="bold">(%)</content><BR>                                 </td><BR>                                 <td align="center"><BR>                                    <content styleCode="bold">5-year rate</content><BR>                                 </td><BR>                                 <td align="center"><BR>                                    <content styleCode="bold">Events</content><BR>                                    <br/><BR>                                    <content styleCode="bold">(%)</content><BR>                                 </td><BR>                                 <td align="center"><BR>                                    <content styleCode="bold">5-year rate</content><BR>                                 </td><BR>                                 <td align="center"><BR>                                    <content styleCode="bold">(95% CI)</content><BR>                                 </td><BR>                                 <td align="center"><BR>                                    <content styleCode="bold italics">P</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Toprule ">Disease-free survival<sup>1</sup><BR>                                 </td><BR>                                 <td styleCode="Toprule ">ITT</td><BR>                                 <td styleCode="Toprule " align="center">445 (18.1)</td><BR>                                 <td styleCode="Toprule " align="center">87.4</td><BR>                                 <td styleCode="Toprule " align="center">500 (20.3)</td><BR>                                 <td styleCode="Toprule " align="center">84.7</td><BR>                                 <td styleCode="Toprule " align="center">0.87 (0.76, 0.99)</td><BR>                                 <td styleCode="Toprule " align="center">0.03</td><BR>                              </tr><BR>                              <tr><BR>                                 <td/><BR>                                 <td>Censor</td><BR>                                 <td align="center">445</td><BR>                                 <td align="center">87.4</td><BR>                                 <td align="center">483</td><BR>                                 <td align="center">84.2</td><BR>                                 <td align="center">0.84 (0.73, 0.95)</td><BR>                                 <td align="center"/><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	0 positive nodes</td><BR>                                 <td>ITT</td><BR>                                 <td align="center">165</td><BR>                                 <td align="center">92.2</td><BR>                                 <td align="center">189</td><BR>                                 <td align="center">90.3</td><BR>                                 <td align="center">0.88 (0.72, 1.09)</td><BR>                                 <td align="center"/><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	1-3 positive nodes</td><BR>                                 <td>ITT</td><BR>                                 <td align="center">151</td><BR>                                 <td align="center">85.6</td><BR>                                 <td align="center">163</td><BR>                                 <td align="center">83.0</td><BR>                                 <td align="center">0.85 (0.68, 1.06)</td><BR>                                 <td align="center"/><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	&gt;=4 positive nodes</td><BR>                                 <td>ITT</td><BR>                                 <td align="center">123</td><BR>                                 <td align="center">71.2</td><BR>                                 <td align="center">142</td><BR>                                 <td align="center">62.6</td><BR>                                 <td align="center">0.81 (0.64, 1.03)</td><BR>                                 <td align="center"/><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	Adjuvant chemotherapy</td><BR>                                 <td>ITT</td><BR>                                 <td align="center">119</td><BR>                                 <td align="center">86.4</td><BR>                                 <td align="center">150</td><BR>                                 <td align="center">80.6</td><BR>                                 <td align="center">0.77 (0.60, 0.98)</td><BR>                                 <td align="center"/><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	No chemotherapy</td><BR>                                 <td>ITT</td><BR>                                 <td align="center">326</td><BR>                                 <td align="center">87.8</td><BR>                                 <td align="center">350</td><BR>                                 <td align="center">86.1</td><BR>                                 <td align="center">0.91 (0.78, 1.06)</td><BR>                                 <td align="center"/><BR>                              </tr><BR>                              <tr><BR>                                 <td>Systemic DFS<sup>2</sup><BR>                                 </td><BR>                                 <td>ITT</td><BR>                                 <td align="center">401</td><BR>                                 <td align="center">88.5</td><BR>                                 <td align="center">446</td><BR>                                 <td align="center">86.6</td><BR>                                 <td align="center">0.88 (0.77,1.01)</td><BR>                                 <td align="center"/><BR>                              </tr><BR>                              <tr><BR>                                 <td>Time to distant metastasis<sup>3</sup><BR>                                 </td><BR>                                 <td>ITT</td><BR>                                 <td align="center">257</td><BR>                                 <td align="center">92.4</td><BR>                                 <td align="center">298</td><BR>                                 <td align="center">90.1</td><BR>                                 <td align="center">0.85 (0.72, 1.00)</td><BR>                                 <td align="center"/><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	Adjuvant chemotherapy</td><BR>                                 <td>ITT</td><BR>                                 <td align="center">84</td><BR>                                 <td align="center">-</td><BR>                                 <td align="center">109</td><BR>                                 <td align="center">-</td><BR>                                 <td align="center">0.75 (0.56-1.00)</td><BR>                                 <td align="center"/><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	No chemotherapy</td><BR>                                 <td>ITT</td><BR>                                 <td align="center">173</td><BR>                                 <td align="center">-</td><BR>                                 <td align="center">189</td><BR>                                 <td align="center">-</td><BR>                                 <td align="center">0.90 (0.73,1.11)</td><BR>                                 <td align="center"/><BR>                              </tr><BR>                              <tr><BR>                                 <td>Distant DFS<sup>4</sup><BR>                                 </td><BR>                                 <td>ITT</td><BR>                                 <td align="center">385</td><BR>                                 <td align="center">89.0</td><BR>                                 <td align="center">432</td><BR>                                 <td align="center">87.1</td><BR>                                 <td align="center">0.87 (0.76,1.00)</td><BR>                                 <td align="center"/><BR>                              </tr><BR>                              <tr><BR>                                 <td>Contralateral breast cancer</td><BR>                                 <td>ITT</td><BR>                                 <td align="center">34</td><BR>                                 <td align="center">99.2</td><BR>                                 <td align="center">44</td><BR>                                 <td align="center">98.6</td><BR>                                 <td align="center">0.76 (0.49, 1.19)</td><BR>                                 <td align="center"/><BR>                              </tr><BR>                              <tr><BR>                                 <td>Overall survival</td><BR>                                 <td>ITT</td><BR>                                 <td align="center">303</td><BR>                                 <td align="center">91.8</td><BR>                                 <td align="center">343</td><BR>                                 <td align="center">90.9</td><BR>                                 <td align="center">0.87 (0.75, 1.02)</td><BR>                                 <td align="center"/><BR>                              </tr><BR>                              <tr><BR>                                 <td/><BR>                                 <td>Censor</td><BR>                                 <td align="center">303</td><BR>                                 <td align="center">91.8</td><BR>                                 <td align="center">338</td><BR>                                 <td align="center">90.1</td><BR>                                 <td align="center">0.82 (0.70, 0.96)</td><BR>                                 <td align="center"/><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	0 positive nodes</td><BR>                                 <td>ITT</td><BR>                                 <td align="center">107</td><BR>                                 <td align="center">95.2</td><BR>                                 <td align="center">121</td><BR>                                 <td align="center">94.8</td><BR>                                 <td align="center">0.90 (0.69.1.16)</td><BR>                                 <td align="center"/><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	1-3 positive nodes</td><BR>                                 <td>ITT</td><BR>                                 <td align="center">99</td><BR>                                 <td align="center">90.8</td><BR>                                 <td align="center">114</td><BR>                                 <td align="center">90.6</td><BR>                                 <td align="center">0.81(0.62,1.06)</td><BR>                                 <td align="center"/><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	&gt;=4 positive nodes</td><BR>                                 <td>ITT</td><BR>                                 <td align="center">92</td><BR>                                 <td align="center">80.2</td><BR>                                 <td align="center">104</td><BR>                                 <td align="center">73.6</td><BR>                                 <td align="center">0.86 (0.65, 1.14)</td><BR>                                 <td align="center"/><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	Adjuvant chemotherapy</td><BR>                                 <td>ITT</td><BR>                                 <td align="center">76</td><BR>                                 <td align="center">91.5</td><BR>                                 <td align="center">96</td><BR>                                 <td align="center">88.4</td><BR>                                 <td align="center">0.79 (0.58, 1.06)</td><BR>                                 <td align="center"/><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	No chemotherapy</td><BR>                                 <td>ITT</td><BR>                                 <td align="center">227</td><BR>                                 <td align="center">91.9</td><BR>                                 <td align="center">247</td><BR>                                 <td align="center">91.8</td><BR>                                 <td align="center">0.91 (0.76, 1.08)</td><BR>                                 <td align="center"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Toprule " colspan="8">Definition of:<br/><BR>                                    <sup>1</sup>&#160;Disease-free survival: Interval from randomization to earliest event of invasive loco-regional recurrence, distant metastasis, invasive contralateral breast cancer, or death without a prior event<br/><BR>                                    <sup>2</sup>&#160;Systemic disease-free survival: Interval from randomization to invasive regional recurrence, distant metastasis, or death without a prior cancer event<br/><BR>                                    <sup>3</sup>&#160;Time to distant metastasis: Interval from randomization to distant metastasis<br/><BR>                                    <sup>4</sup>&#160;Distant disease-free survival: Interval from randomization to earlier event of relapse in a distant site or death from any cause<br/>ITT analysis ignores selective crossover in tamoxifen arms<br/>Censored analysis censors follow-up at the date of selective crossover in 632 patients who crossed to Femara or another aromatase inhibitor after the tamoxifen arms were unblinded in 2005</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>Figure 1 shows the Kaplan-Meier curves for Disease-Free Survival Monotherapy Analysis<BR>                        <BR>                           Figure 1  Disease-Free Survival (Median follow-up 73 months, ITT Approach)<BR>                        <BR>                        DFS events defined as loco-regional recurrence, distant metastasis, invasive contralateral breast cancer, or death from any cause (i.e., definition excludes second non-breast primary cancers).<BR>                        The medians of overall survival for both arms were not reached for the Monotherapy Arms Analysis (MAA). There was no statistically significant difference in overall survival. The hazard ratio for survival in the Femara arm compared to the tamoxifen arm was 0.87, with 95% CI (0.75, 1.02) (see Table 6).<BR>                        There were no significant differences in DFS, OS, SDFS, and Distant DFS from switch in the Sequential Treatments Analysis with respect to either monotherapy (e.g., [Tamoxifen 2 years followed by] Femara 3 years versus tamoxifen beyond 2 years, DFS HR 0.89; 97.5% CI 0.68, 1.15 and [Femara 2 years followed by] tamoxifen 3 years versus Femara beyond 2 years, DFS HR 0.93; 97.5% CI 0.71, 1.22).<BR>                        There were no significant differences in DFS, OS, SDFS, and Distant DFS from randomization in the Sequential Treatments Analyses.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     <BR>                        1<BR>                        4<BR>                        .2 Extended Adjuvant Treatment of Early Breast Cancer<BR>                        , Median Treatment Duration of 24 M<BR>                        onths<BR>                     <BR>                     <BR>                        A double-blind, randomized, placebo-controlled trial of Femara was performed in over 5,100 postmenopausal women with receptor-positive or unknown primary breast cancer who were disease free after 5 years of adjuvant treatment with tamoxifen.<BR>                        The planned duration of treatment for patients in the study was 5 years, but the trial was terminated early because of an interim analysis showing a favorable Femara effect on time without recurrence or contralateral breast cancer. At the time of unblinding, women had been followed for a median of 28 months, 30% of patients had completed 3 or more years of follow-up and less than 1% of patients had completed 5 years of follow-up.<BR>                        Selected baseline characteristics for the study population are shown in Table 7.<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><BR>                           <caption>Table 7:  Selected Study Population Demographics (Modified ITT Population)</caption><BR>                           <col width="217"/><BR>                           <col width="144"/><BR>                           <col width="188"/><BR>                           <tbody><BR>                              <tr><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">Baseline Status</content><BR>                                 </td><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">Femara</content><BR>                                 </td><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">Placebo</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"/><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">N=2582</content><BR>                                 </td><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">N=2586</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Toprule " valign="bottom"><BR>                                    <content styleCode="bold">Hormone Receptor Status (%)</content><BR>                                 </td><BR>                                 <td styleCode="Toprule " valign="bottom" align="center"/><BR>                                 <td styleCode="Toprule " valign="bottom" align="center"/><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	ER+ and/or PgR+</td><BR>                                 <td valign="bottom">98</td><BR>                                 <td valign="bottom">98</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	Both Unknown</td><BR>                                 <td valign="bottom">2</td><BR>                                 <td valign="bottom">2</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">Nodal Status (%)</content><BR>                                 </td><BR>                                 <td valign="bottom" align="center"/><BR>                                 <td valign="bottom" align="center"/><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	Node Negative</td><BR>                                 <td valign="bottom">50</td><BR>                                 <td valign="bottom">50</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	Node Positive</td><BR>                                 <td valign="bottom">46</td><BR>                                 <td valign="bottom">46</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	Nodal Status Unknown</td><BR>                                 <td valign="bottom">4</td><BR>                                 <td valign="bottom">4</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">Chemotherapy</content><BR>                                 </td><BR>                                 <td valign="bottom">46</td><BR>                                 <td valign="bottom">46</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>Table 8 shows the study results. Disease-free survival was measured as the time from randomization to the earliest event of loco-regional or distant recurrence of the primary disease or development of contralateral breast cancer or death. DFS by hormone receptor status, nodal status and adjuvant chemotherapy were similar to the overall results. Data were premature for an analysis of survival.<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><BR>                           <caption>Table 8:  Extended Adjuvant Study Results</caption><BR>                           <col width="321"/><BR>                           <col width="105"/><BR>                           <col width="84"/><BR>                           <col width="138"/><BR>                           <col width="78"/><BR>                           <col width="24"/><BR>                           <tbody><BR>                              <tr><BR>                                 <td/><BR>                                 <td><BR>                                    <content styleCode="bold">Femara</content><BR>                                    <content styleCode="bold"><BR>                                       <br/>N = 2582</content><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold">Placebo</content><BR>                                    <content styleCode="bold"><BR>                                       <br/>N = 2586</content><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold">Hazard Ratio</content><BR>                                    <content styleCode="bold"><BR>                                       <br/>(95% CI)</content><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold italics">P</content><BR>                                    <content styleCode="bold">-Value</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Toprule "><BR>                                    <content styleCode="bold">Disease Free Survival (DFS)</content><BR>                                    <content styleCode="bold"><BR>                                       <sup>1</sup><BR>                                    </content><BR>                                    <content styleCode="bold"><BR>                                       <sup>&#160;</sup><BR>                                    </content><BR>                                    <content styleCode="bold">Events</content><BR>                                 </td><BR>                                 <td styleCode="Toprule " valign="bottom">122 (4.7%)</td><BR>                                 <td styleCode="Toprule " valign="bottom">193 (7.5%)</td><BR>                                 <td styleCode="Toprule " valign="bottom">0.62 (0.49, 0.78)<sup>2</sup><BR>                                 </td><BR>                                 <td styleCode="Toprule " valign="bottom">0.00003</td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	Local Breast Recurrence</td><BR>                                 <td>9</td><BR>                                 <td>22</td><BR>                                 <td/><BR>                                 <td/><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	Local Chest Wall Recurrence</td><BR>                                 <td>2</td><BR>                                 <td>8</td><BR>                                 <td/><BR>                                 <td/><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	Regional Recurrence</td><BR>                                 <td>7</td><BR>                                 <td>4</td><BR>                                 <td/><BR>                                 <td>&#160;</td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	Distant Recurrence</td><BR>                                 <td>55</td><BR>                                 <td>92</td><BR>                                 <td>0.61 (0.44 - 0.84)</td><BR>                                 <td>0.003</td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	Contralateral Breast Cancer</td><BR>                                 <td>19</td><BR>                                 <td>29</td><BR>                                 <td/><BR>                                 <td/><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	Deaths Without Recurrence or Contralateral <BR>		&#160;&#160;&#160;&#160;&#160;<BR>	Breast Cancer</td><BR>                                 <td>30</td><BR>                                 <td>38</td><BR>                                 <td valign="bottom"/><BR>                                 <td valign="bottom"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Toprule " colspan="6">CI = confidence interval for hazard ratio. Hazard ratio of less than 1.0 indicates difference in favor of Femara (lesser&#160;risk of recurrence); hazard ratio greater than 1.0 indicates difference in favor of placebo (higher risk of recurrence with Femara).<br/><BR>                                    <sup>1</sup>&#160;First event of loco-regional recurrence, distant relapse, contralateral breast cancer or death from any cause <br/><BR>                                    <sup>2</sup>&#160;Analysis stratified by receptor status, nodal status and prior adjuvant chemotherapy (stratification factors as at randomization). <content styleCode="italics">P</content>-value based on stratified logrank test.</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                     <BR><BR><BR><BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     <BR>                        14.3 <BR>                        Updated Analyses of <BR>                        Extended<BR>                         Adjuvant Treatment of Early Breast Cancer, Median Treatment Duration of <BR>                        60<BR>                         Months<BR>                     <BR>                     <BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><BR>                           <caption>Table 9: &#160;Update of Extended Adjuvant Study Results</caption><BR>                           <col width="292"/><BR>                           <col width="91"/><BR>                           <col width="91"/><BR>                           <col width="126"/><BR>                           <col width="71"/><BR>                           <col width="28"/><BR>                           <tbody><BR>                              <tr><BR>                                 <td/><BR>                                 <td><BR>                                    <content styleCode="bold">Femara</content><BR>                                    <content styleCode="bold"><BR>                                       <br/>N = 2582</content><BR>                                    <br/><BR>                                    <content styleCode="bold">(%)</content><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold">Placebo</content><BR>                                    <content styleCode="bold"><BR>                                       <br/>N = 2586</content><BR>                                    <br/><BR>                                    <content styleCode="bold">(%)</content><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold">Hazard Ratio</content><BR>                                    <content styleCode="bold"><BR>                                       <sup>1</sup><BR>                                    </content><BR>                                    <content styleCode="bold"><BR>                                       <br/>(95% CI)</content><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold italics">P</content><BR>                                    <content styleCode="bold">-Value</content><BR>                                    <content styleCode="bold"><BR>                                       <sup>2</sup><BR>                                    </content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Toprule "><BR>                                    <content styleCode="bold">Disease Free Survival (DFS) events</content><BR>                                    <content styleCode="bold"><BR>                                       <sup>3</sup><BR>                                    </content><BR>                                 </td><BR>                                 <td styleCode="Toprule " valign="bottom">344 (13.3)</td><BR>                                 <td styleCode="Toprule " valign="bottom">402 (15.5)</td><BR>                                 <td styleCode="Toprule " valign="bottom">0.89 (0.77, 1.03)</td><BR>                                 <td styleCode="Toprule " valign="bottom">0.12</td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <content styleCode="bold">Breast cancer recurrence</content><BR>                                    <br/>(Protocol definition of DFS events<sup>4</sup>) </td><BR>                                 <td>209</td><BR>                                 <td>286</td><BR>                                 <td>0.75 (0.63, 0.89)</td><BR>                                 <td>0.001</td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	Local Breast Recurrence</td><BR>                                 <td>15</td><BR>                                 <td>44</td><BR>                                 <td/><BR>                                 <td/><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	Local Chest Wall Recurrence</td><BR>                                 <td>6</td><BR>                                 <td>14</td><BR>                                 <td/><BR>                                 <td/><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	Regional Recurrence</td><BR>                                 <td>10</td><BR>                                 <td>8</td><BR>                                 <td/><BR>                                 <td>&#160;</td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	Distant Recurrence</td><BR>                                 <td>140</td><BR>                                 <td>167</td><BR>                                 <td/><BR>                                 <td/><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	Distant recurrence (first or subsequent <BR>		&#160;&#160;&#160;&#160;&#160;<BR>	events)<br/><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	Contralateral Breast Cancer</td><BR>                                 <td>142<br/><BR>                                    <br/>37 </td><BR>                                 <td>169<br/><BR>                                    <br/>53</td><BR>                                 <td>0.88 (0.70,1.10)</td><BR>                                 <td>0.246</td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	Deaths Without Recurrence or <BR>		&#160;&#160;&#160;&#160;&#160;<BR>	Contralateral Breast Cancer</td><BR>                                 <td>135</td><BR>                                 <td>116</td><BR>                                 <td valign="bottom"/><BR>                                 <td valign="bottom"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Toprule " colspan="6"><BR>                                    <sup>1</sup>&#160;Adjusted by receptor status, nodal status and prior chemotherapy<br/><BR>                                    <sup>2</sup> Stratified logrank test, stratified by receptor status, nodal status and prior chemotherapy<br/><BR>                                    <sup>3</sup> DFS events defined as earliest of loco-regional recurrence, distant metastasis, contralateral breast cancer or death from any cause, and ignoring switches to Femara in 60% of the placebo arm.<br/><BR>                                    <sup>4 </sup>Protocol definition does not include deaths from any cause&#160;</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>Updated analyses were conducted at a median follow-up of 62 months. In the Femara arm, 71% of the patients were treated for a least 3 years and 58% of patients completed at least 4.5 years of extended adjuvant treatment. After the unblinding of the study at a median follow-up of 28 months, approximately 60% of the selected patients in the placebo arm opted to switch to Femara. <BR>                        In this updated analysis shown in Table 9, Femara significantly reduced the risk of breast cancer recurrence or contralateral breast cancer compared with placebo (HR 0.75; 95% CI 0.63, 0.89; P=0.001). However, in the updated DFS analysis (interval between randomization and earliest event of loco-regional recurrence, distant metastasis, contralateral breast cancer, or death from any cause) the treatment difference was heavily diluted by 60% of the patients in the placebo arm switching to Femara and accounting for 64% of the total placebo patient- years of follow-up. Ignoring these switches, the risk of DFS event was reduced by a non-significant 11% (HR 0.89; 95% CI 0.77, 1.03). There was no significant difference in distant disease-free survival or overall survival. <BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     <BR>                        1<BR>                        4<BR>                        .<BR>                        4<BR>                         <BR>                        First-Line Tre<BR>                        atment of Advanced Breast Cancer<BR>                     <BR>                     <BR>                        A randomized, double-blind, multinational trial compared Femara 2.5 mg with tamoxifen 20 mg in 916 postmenopausal patients with locally advanced (Stage IIIB or loco-regional recurrence not amenable to treatment with surgery or radiation) or metastatic breast cancer. Time to progression (TTP) was the primary endpoint of the trial. Selected baseline characteristics for this study are shown in Table 10.<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><BR>                           <caption>Table 10:  Selected Study Population Demographics</caption><BR>                           <col width="248"/><BR>                           <col width="160"/><BR>                           <col width="179"/><BR>                           <tbody><BR>                              <tr><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">Baseline Status</content><BR>                                 </td><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">Femara</content><BR>                                 </td><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">t</content><BR>                                    <content styleCode="bold">amoxifen</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"/><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">N=458</content><BR>                                 </td><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">N=458</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Toprule " valign="bottom"><BR>                                    <content styleCode="bold">Stage of Disease</content><BR>                                 </td><BR>                                 <td styleCode="Toprule " valign="bottom" align="center"/><BR>                                 <td styleCode="Toprule " valign="bottom" align="center"/><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	IIIB</td><BR>                                 <td valign="bottom">6%</td><BR>                                 <td valign="bottom">7%</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	IV</td><BR>                                 <td valign="bottom">93%</td><BR>                                 <td valign="bottom">92%</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">Receptor Status</content><BR>                                 </td><BR>                                 <td valign="bottom" align="center"/><BR>                                 <td valign="bottom" align="center"/><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	ER and PgR&#160;Positive</td><BR>                                 <td valign="bottom">38%</td><BR>                                 <td valign="bottom">41%</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	ER or PgR Positive</td><BR>                                 <td valign="bottom">26%</td><BR>                                 <td valign="bottom">26%</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	Both Unknown</td><BR>                                 <td valign="bottom">34%</td><BR>                                 <td valign="bottom">33%</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	ER<sup>-</sup> or PgR<sup>-</sup>/Other Unknown</td><BR>                                 <td valign="bottom">&lt;1%</td><BR>                                 <td valign="bottom">0</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">Previous Antiestrogen Therapy</content><BR>                                 </td><BR>                                 <td valign="bottom" align="center"/><BR>                                 <td valign="bottom" align="center"/><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	Adjuvant</td><BR>                                 <td valign="bottom">19%</td><BR>                                 <td valign="bottom">18%</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	None</td><BR>                                 <td valign="bottom">81%</td><BR>                                 <td valign="bottom">82%</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">Dominant Site of Disease</content><BR>                                 </td><BR>                                 <td valign="bottom" align="center"/><BR>                                 <td valign="bottom" align="center"/><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	Soft Tissue</td><BR>                                 <td valign="bottom">25%</td><BR>                                 <td valign="bottom">25%</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	Bone</td><BR>                                 <td valign="bottom">32%</td><BR>                                 <td valign="bottom">29%</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	Viscera</td><BR>                                 <td valign="bottom">43%</td><BR>                                 <td valign="bottom">46%</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>Femara was superior to tamoxifen in TTP and rate of objective tumor response (see Table 11).<BR>                        Table 11 summarizes the results of the trial, with a total median follow-up of approximately 32 months. (All analyses are unadjusted and use 2-sided P-values.)<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><BR>                           <caption>Table 11:  Results of First-Line Treatment of Advanced Breast Cancer&#160;</caption><BR>                           <col width="247"/><BR>                           <col width="120"/><BR>                           <col width="112"/><BR>                           <col width="144"/><BR>                           <tbody><BR>                              <tr><BR>                                 <td valign="bottom"/><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">Femara</content><BR>                                 </td><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">tamoxifen</content><BR>                                 </td><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">Hazard or Odds</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"/><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">2.5 mg</content><BR>                                 </td><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">20 mg</content><BR>                                 </td><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">Ratio (95% CI)</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"/><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">N=453</content><BR>                                 </td><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">N=454</content><BR>                                 </td><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold italics">P</content><BR>                                    <content styleCode="bold">-Value (2-Sided)</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Toprule " valign="bottom"/><BR>                                 <td styleCode="Toprule " valign="bottom"/><BR>                                 <td styleCode="Toprule " valign="bottom"/><BR>                                 <td styleCode="Toprule " valign="bottom"/><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">Median Time to Progression</content><BR>                                 </td><BR>                                 <td valign="bottom">9.4 months</td><BR>                                 <td valign="bottom">6.0 months</td><BR>                                 <td valign="bottom">0.72 (0.62, 0.83)<sup>1</sup><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"/><BR>                                 <td valign="bottom"/><BR>                                 <td valign="bottom"/><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="italics">P</content>&lt;0.0001</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">Objective Response Rate</content><BR>                                 </td><BR>                                 <td valign="bottom"/><BR>                                 <td valign="bottom"/><BR>                                 <td valign="bottom"/><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	(CR + PR)</td><BR>                                 <td valign="bottom">145 (32%)</td><BR>                                 <td valign="bottom">95 (21%)</td><BR>                                 <td valign="bottom">1.77 (1.31, 2.39)<sup>2</sup><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"/><BR>                                 <td valign="bottom"/><BR>                                 <td valign="bottom"/><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="italics">P</content>=0.0002</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	(CR)</td><BR>                                 <td valign="bottom">42 (9%)</td><BR>                                 <td valign="bottom">15 (3%)</td><BR>                                 <td valign="bottom">2.99 (1.63, 5.47)<sup>2</sup><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"/><BR>                                 <td valign="bottom"/><BR>                                 <td valign="bottom"/><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="italics">P</content>=0.0004</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">Duration of Objective Response</content><BR>                                 </td><BR>                                 <td valign="bottom"/><BR>                                 <td valign="bottom"/><BR>                                 <td valign="bottom"/><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	Median</td><BR>                                 <td valign="bottom">18 months </td><BR>                                 <td valign="bottom">16 months </td><BR>                                 <td valign="bottom"/><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"/><BR>                                 <td valign="bottom">(N=145)</td><BR>                                 <td valign="bottom">(N=95)</td><BR>                                 <td valign="bottom"/><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">Overall Survival</content><BR>                                 </td><BR>                                 <td valign="bottom">35 months </td><BR>                                 <td valign="bottom">32 months</td><BR>                                 <td valign="bottom"/><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"/><BR>                                 <td valign="bottom">(N=458)</td><BR>                                 <td valign="bottom">(N=458)</td><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="italics">P</content>=0.5136<sup>3</sup><BR>                                 </td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR><BR>                           1 Hazard ratio<BR>                        <BR>                           2 Odds ratio<BR>                        <BR>                           3 Overall logrank test<BR>                        Figure 2 shows the Kaplan-Meier curves for TTP.<BR>                        <BR>                           Figure 2  Kaplan-Meier Estimates of Time to Progression (Tamoxifen Study)<BR>                        <BR>                        Table 12 shows results in the subgroup of women who had received prior antiestrogen adjuvant therapy, Table 13 , results by disease site and Table 14, the results by receptor status.<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><BR>                           <caption>Table 12:  Efficacy in Patients Who Received Prior&#160;Antiestrogen Therapy</caption><BR>                           <col width="310"/><BR>                           <col width="161"/><BR>                           <col width="178"/><BR>                           <tbody><BR>                              <tr><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">Variable</content><BR>                                 </td><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">Femara </content><BR>                                 </td><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">t</content><BR>                                    <content styleCode="bold">amoxifen</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"/><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">2.5 mg</content><BR>                                 </td><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">20 mg</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"/><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">N=84</content><BR>                                 </td><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">N=83</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Toprule " valign="bottom"><BR>                                    <content styleCode="bold">Median Time to Progression</content> (95% CI)</td><BR>                                 <td styleCode="Toprule " valign="bottom">8.9 months (6.2, 12.5) </td><BR>                                 <td styleCode="Toprule " valign="bottom">5.9 months (3.2, 6.2)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	Hazard Ratio for TTP (95% CI) </td><BR>                                 <td colspan="2" valign="bottom" align="center">0.60 (0.43, 0.84)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">Objective Response Rate</content><BR>                                 </td><BR>                                 <td valign="bottom"/><BR>                                 <td valign="bottom"/><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	(CR + PR)</td><BR>                                 <td valign="bottom">22 (26%)</td><BR>                                 <td valign="bottom">7 (8%)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	Odds Ratio for&#160;Response (95% CI)</td><BR>                                 <td colspan="2" valign="bottom" align="center">3.85 (1.50, 9.60)</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>Hazard ratio less than 1 or odds ratio greater than 1 favors Femara; hazard ratio greater than 1 or odds ratio less than 1 favors tamoxifen.<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><BR>                           <caption>Table 13:  Efficacy by Disease Site</caption><BR>                           <col width="228"/><BR>                           <col width="168"/><BR>                           <col width="164"/><BR>                           <tbody><BR>                              <tr><BR>                                 <td valign="bottom"/><BR>                                 <td valign="bottom" align="center"><BR>                                    <content styleCode="bold">Femara</content><BR>                                 </td><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">tamoxifen</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"/><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">2.5 mg</content><BR>                                 </td><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">20 mg</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Toprule " valign="bottom"><BR>                                    <content styleCode="bold">Dominant Disease Site</content><BR>                                 </td><BR>                                 <td styleCode="Toprule " valign="bottom"/><BR>                                 <td styleCode="Toprule " valign="bottom"/><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">Soft Tissue:</content><BR>                                 </td><BR>                                 <td valign="bottom">N=113</td><BR>                                 <td valign="bottom">N=115</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	Median TTP</td><BR>                                 <td valign="bottom">12.1 months</td><BR>                                 <td valign="bottom">6.4 months</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	Objective Response Rate</td><BR>                                 <td valign="bottom">50%</td><BR>                                 <td valign="bottom">34%</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">Bone:</content><BR>                                 </td><BR>                                 <td valign="bottom">N=145</td><BR>                                 <td valign="bottom">N=131</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	Median TTP</td><BR>                                 <td valign="bottom">9.5 months</td><BR>                                 <td valign="bottom">6.3 months</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	Objective Response Rate</td><BR>                                 <td valign="bottom">23%</td><BR>                                 <td valign="bottom">15%</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">Viscera:</content><BR>                                 </td><BR>                                 <td valign="bottom">N=195</td><BR>                                 <td valign="bottom">N=208</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	Median TTP</td><BR>                                 <td valign="bottom">8.3 months</td><BR>                                 <td valign="bottom">4.6 months</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	Objective Response Rate</td><BR>                                 <td valign="bottom">28%</td><BR>                                 <td valign="bottom">17%</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR><BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><BR>                           <caption>Table 14:  Efficacy by Receptor Status</caption><BR>                           <col width="295"/><BR>                           <col width="168"/><BR>                           <col width="204"/><BR>                           <tbody><BR>                              <tr><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">Variable</content><BR>                                 </td><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">Femara</content><BR>                                 </td><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">tamoxifen</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"/><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">2.5 mg</content><BR>                                 </td><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">20 mg</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Toprule " valign="bottom"><BR>                                    <content styleCode="bold">Receptor Positive</content><BR>                                 </td><BR>                                 <td styleCode="Toprule " valign="bottom">N=294</td><BR>                                 <td styleCode="Toprule " valign="bottom">N=305</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	Median Time to&#160;Progression (95% CI)</td><BR>                                 <td valign="bottom">9.4 months (8.9, 11.8)</td><BR>                                 <td valign="bottom">6.0 months (5.1, 8.5)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	Hazard Ratio for TTP (95% CI)</td><BR>                                 <td valign="bottom">0.69 (0.58, 0.83)</td><BR>                                 <td valign="bottom"/><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	Objective Response Rate (CR+PR)</td><BR>                                 <td valign="bottom">97 (33%)</td><BR>                                 <td valign="bottom">66 (22%)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	Odds Ratio for Response 95% CI)</td><BR>                                 <td valign="bottom">1.78 (1.20, 2.60)</td><BR>                                 <td valign="bottom"/><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">Receptor Unknown</content><BR>                                 </td><BR>                                 <td valign="bottom">N=159</td><BR>                                 <td valign="bottom">N=149</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	Median Time to&#160;Progression (95% CI)</td><BR>                                 <td valign="bottom">9.2 months (6.1, 12.3)</td><BR>                                 <td valign="bottom">6.0 months (4.1, 6.4)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	Hazard Ratio for TTP (95% CI)</td><BR>                                 <td valign="bottom">&#160;0.77 (0.60, 0.99)</td><BR>                                 <td valign="bottom"/><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	Objective Response Rate (CR+PR)</td><BR>                                 <td valign="bottom">48 (30%)</td><BR>                                 <td valign="bottom">29 (20%)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	Odds Ratio for Response (95% CI)</td><BR>                                 <td valign="bottom">1.79 (1.10, 3.00)</td><BR>                                 <td valign="bottom"/><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>Hazard ratio less than 1 or odds ratio greater than 1 favors Femara; hazard ratio greater than 1 or odds ratio less than 1 favors tamoxifen.<BR>                        Figure 3 shows the Kaplan-Meier curves for survival.<BR>                        <BR>                           Figure 3  Survival by Randomized Treatment Arm<BR>                        <BR>                        <BR>                           Legend: Randomized Femara: n=458, events 57%, median overall survival 35 months (95% CI 32 to 38 months)<BR>                        Randomized tamoxifen: n=458, events 57%, median overall survival 32 months (95% CI 28 to 37 months)<BR>                        Overall logrank P=0.5136 (i.e., there was no significant difference between treatment arms in overall survival).<BR>                        The median overall survival was 35 months for the Femara group and 32 months for the tamoxifen group, with a P-value 0.5136. Study design allowed patients to cross over upon progression to the other therapy. Approximately 50% of patients crossed over to the opposite treatment arm and almost all patients who crossed over had done so by 36 months. The median time to crossover was 17 months (Femara to tamoxifen) and 13 months (tamoxifen to Femara). In patients who did not cross over to the opposite treatment arm, median survival was 35 months with Femara (n=219, 95% Cl 29 to 43 months) vs 20 months with tamoxifen (n=229, 95% Cl 16 to 26 months).<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     <BR>                        1<BR>                        4<BR>                        .<BR>                        5<BR>                         Second-Line Treatment of Advanced Breast Cancer<BR>                     <BR>                     <BR>                        Femara was initially studied at doses of 0.1 mg to 5.0 mg daily in six non-comparative Phase I/II trials in 181 postmenopausal estrogen/progesterone receptor positive or unknown advanced breast cancer patients previously treated with at least antiestrogen therapy. Patients had received other hormonal therapies and also may have received cytotoxic therapy. Eight (20%) of forty patients treated with Femara 2.5 mg daily in Phase I/II trials achieved an objective tumor response (complete or partial response).<BR>                        Two large randomized, controlled, multinational (predominantly European) trials were conducted in patients with advanced breast cancer who had progressed despite antiestrogen therapy. Patients were randomized to Femara 0.5 mg daily, Femara 2.5 mg daily, or a comparator (megestrol acetate 160 mg daily in one study; and aminoglutethimide 250 mg b.i.d. with corticosteroid supplementation in the other study). In each study over 60% of the patients had received therapeutic antiestrogens, and about one-fifth of these patients had an objective response. The megestrol acetate controlled study was double-blind; the other study was open label. Selected baseline characteristics for each study are shown in Table 15.<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><BR>                           <caption>Table 15:  Selected Study Population Demographics</caption><BR>                           <col width="259"/><BR>                           <col width="198"/><BR>                           <col width="192"/><BR>                           <tbody><BR>                              <tr><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">Parameter</content><BR>                                 </td><BR>                                 <td valign="bottom" align="center"><BR>                                    <content styleCode="bold">megestrol acetate</content><BR>                                 </td><BR>                                 <td valign="bottom" align="center"><BR>                                    <content styleCode="bold">aminoglutethimide</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"/><BR>                                 <td valign="bottom" align="center"><BR>                                    <content styleCode="bold">study</content><BR>                                 </td><BR>                                 <td valign="bottom" align="center"><BR>                                    <content styleCode="bold">study</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Toprule " valign="bottom"><BR>                                    <content styleCode="bold">No. of Participants</content><BR>                                 </td><BR>                                 <td styleCode="Toprule " valign="bottom" align="center">552</td><BR>                                 <td styleCode="Toprule " valign="bottom" align="center">557</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">Receptor Status</content><BR>                                 </td><BR>                                 <td valign="bottom" align="center"/><BR>                                 <td valign="bottom" align="center"/><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	ER/PR Positive</td><BR>                                 <td valign="bottom" align="center">57%</td><BR>                                 <td valign="bottom" align="center">56%</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	ER/PR Unknown</td><BR>                                 <td valign="bottom" align="center">43%</td><BR>                                 <td valign="bottom" align="center">44%</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">Previous Therapy</content><BR>                                 </td><BR>                                 <td valign="bottom" align="center"/><BR>                                 <td valign="bottom" align="center"/><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	Adjuvant Only</td><BR>                                 <td valign="bottom" align="center">33%</td><BR>                                 <td valign="bottom" align="center">38%</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	Therapeutic +/- Adj.</td><BR>                                 <td valign="bottom" align="center">66%</td><BR>                                 <td valign="bottom" align="center">62%</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">Sites of Disease</content><BR>                                 </td><BR>                                 <td valign="bottom" align="center"/><BR>                                 <td valign="bottom" align="center"/><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	Soft Tissue</td><BR>                                 <td valign="bottom" align="center">56%</td><BR>                                 <td valign="bottom" align="center">50%</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	Bone</td><BR>                                 <td valign="bottom" align="center">50%</td><BR>                                 <td valign="bottom" align="center">55%</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>		&#160;&#160;&#160;&#160;&#160;<BR>	Viscera</td><BR>                                 <td valign="bottom" align="center">40%</td><BR>                                 <td valign="bottom" align="center">44%</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>Confirmed objective tumor response (complete response plus partial response) was the primary endpoint of the trials. Responses were measured according to the Union Internationale Contre le Cancer (UICC) criteria and verified by independent, blinded review. All responses were confirmed by a second evaluation 4-12 weeks after the documentation of the initial response.<BR>                        Table 16 shows the results for the first trial, with a minimum follow-up of 15 months, that compared Femara 0.5 mg, Femara 2.5 mg, and megestrol acetate 160 mg daily. (All analyses are unadjusted.)<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><BR>                           <caption>Table 16:  Megestrol Acetate Study Results</caption><BR>                           <col width="191"/><BR>                           <col width="112"/><BR>                           <col width="112"/><BR>                           <col width="200"/><BR>                           <tbody><BR>                              <tr><BR>                                 <td valign="bottom"/><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">Femara </content><BR>                                 </td><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">Femara</content><BR>                                 </td><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">megestrol</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"/><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">0.5 mg</content><BR>                                 </td><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">2.5 mg</content><BR>                                 </td><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">acetate</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"/><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">N=188</content><BR>                                 </td><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">N=174</content><BR>                                 </td><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">N=190</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Toprule " valign="bottom"><BR>                                    <content styleCode="bold">Objective Response (CR + PR)</content><BR>                                 </td><BR>                                 <td styleCode="Toprule " valign="bottom">22 (11.7%)</td><BR>                                 <td styleCode="Toprule " valign="bottom">41 (23.6%)</td><BR>                                 <td styleCode="Toprule " valign="bottom">31 (16.3%)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">Median Duration of Response</content><BR>                                 </td><BR>                                 <td valign="bottom">552 days</td><BR>                                 <td valign="bottom">(Not reached)</td><BR>                                 <td valign="bottom">561 days</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">Median Time to Progression</content><BR>                                 </td><BR>                                 <td valign="bottom">154 days</td><BR>                                 <td valign="bottom">170 days</td><BR>                                 <td valign="bottom">168 days</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">Median Survival </content><BR>                                 </td><BR>                                 <td valign="bottom">633 days</td><BR>                                 <td valign="bottom">730 days</td><BR>                                 <td valign="bottom">659 days</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">Odds Ratio for Response</content><BR>                                 </td><BR>                                 <td colspan="2" valign="bottom">Femara 2.5:&#160;Femara 0.5=2.33</td><BR>                                 <td valign="bottom">Femara 2.5: megestrol=1.58</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"/><BR>                                 <td colspan="2" valign="bottom">(95% CI: 1.32, 4.17); <content styleCode="italics">P</content>=0.004*</td><BR>                                 <td valign="bottom">(95% CI: 0.94, 2.66); <content styleCode="italics">P</content>=0.08*</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">Relative Risk of Progression</content><BR>                                 </td><BR>                                 <td colspan="2" valign="bottom">Femara 2.5:&#160;Femara 0.5=0.81</td><BR>                                 <td valign="bottom">Femara 2.5:&#160;megestrol=0.77</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"/><BR>                                 <td colspan="2" valign="bottom">(95% CI: 0.63, 1.03); <content styleCode="italics">P</content>=0.09*</td><BR>                                 <td valign="bottom">(95% CI: 0.60, 0.98);&#160;<content styleCode="italics">P</content>=0.03*</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>* two-sided P-value<BR>                        The Kaplan-Meier curves for progression for the megestrol acetate study are shown in Figure 4.<BR>                        <BR>                           Figure 4  Kaplan-Meier Estimates of Time to Progression (Megestrol Acetate Study)<BR>                        <BR>                        The results for the study comparing Femara to aminoglutethimide, with a minimum follow-up of 9 months, are shown in Table 17. (Unadjusted analyses are used.)<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><BR>                           <caption>Table&#160;17:  Aminoglutethimide Study Results</caption><BR>                           <col width="199"/><BR>                           <col width="96"/><BR>                           <col width="96"/><BR>                           <col width="179"/><BR>                           <tbody><BR>                              <tr><BR>                                 <td valign="bottom"/><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">Femara </content><BR>                                 </td><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">Femara </content><BR>                                 </td><BR>                                 <td valign="bottom"/><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"/><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">0.5 mg</content><BR>                                 </td><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">2.5 mg</content><BR>                                 </td><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">aminoglutethimide</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"/><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">N=193</content><BR>                                 </td><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">N=185</content><BR>                                 </td><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">N=179</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Toprule " valign="bottom"><BR>                                    <content styleCode="bold">Objective Response (CR</content><BR>                                    <content styleCode="bold">&#160;</content><BR>                                    <content styleCode="bold">+</content><BR>                                    <content styleCode="bold">&#160;</content><BR>                                    <content styleCode="bold">PR)</content><BR>                                 </td><BR>                                 <td styleCode="Toprule " valign="bottom">34 (17.6%)</td><BR>                                 <td styleCode="Toprule " valign="bottom">34 (18.4%)</td><BR>                                 <td styleCode="Toprule " valign="bottom">22 (12.3%)</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">Median Duration of Response</content><BR>                                 </td><BR>                                 <td valign="bottom">619 days</td><BR>                                 <td valign="bottom">706 days</td><BR>                                 <td valign="bottom">450 days</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">Median Time to Progression</content><BR>                                 </td><BR>                                 <td valign="bottom">103 days</td><BR>                                 <td valign="bottom">123 days</td><BR>                                 <td valign="bottom">112 days</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">Median Survival </content><BR>                                 </td><BR>                                 <td valign="bottom">636 days</td><BR>                                 <td valign="bottom">792 days</td><BR>                                 <td valign="bottom">592 days</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">Odds Ratio for Response</content><BR>                                 </td><BR>                                 <td colspan="2" valign="bottom">Femara 2.5:&#160;</td><BR>                                 <td valign="bottom">Femara 2.5:&#160;</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"/><BR>                                 <td colspan="2" valign="bottom">Femara 0.5=1.05</td><BR>                                 <td valign="bottom">aminoglutethimide=1.61</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"/><BR>                                 <td colspan="2" valign="bottom">(95% CI: 0.62, 1.79); <content styleCode="italics">P</content>=0.85*</td><BR>                                 <td valign="bottom">(95% CI: 0.90, 2.87); <content styleCode="italics">P</content>=0.11*</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"><BR>                                    <content styleCode="bold">Relative Risk of Progression</content><BR>                                 </td><BR>                                 <td colspan="2" valign="bottom">Femara 2.5: </td><BR>                                 <td valign="bottom">Femara 2.5:&#160;</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"/><BR>                                 <td colspan="2" valign="bottom">Femara 0.5=0.86</td><BR>                                 <td valign="bottom">aminoglutethimide=0.74</td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="bottom"/><BR>                                 <td colspan="2" valign="bottom">(95% CI: 0.68, 1.11); <content styleCode="italics">P</content>=0.25*</td><BR>                                 <td valign="bottom">(95% CI: 0.57, 0.94); <content styleCode="italics">P</content>=0.02*</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>*two-sided P-value<BR>                        The Kaplan-Meier curves for progression for the aminoglutethimide study is shown in Figure 5.<BR>                        <BR>                           Figure 5 Kaplan-Meier Estimates of Time to Progression (Aminoglutethimide Study)<BR>                        <BR>                     <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>